Currently, intravitreal injections (IVI) of VEGF inhibitors, including ranibizumab (Lucentis, Genentech Inc., South San Francisco, CA, USA) and aflibercept (EYLEA-Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA and Bayer Healthcare Pharmaceuticals, Berlin, Germany) are mainstream and guideline-indicated treatments for diabetic macular edema (DME) [4]. The gene discussed is VEGFA; the disease is diabetic macular edema.